Home » Topics » BioWorld Science

BioWorld Science
RSS

Sanofi achieves KEAP1/Nrf2 inhibition with bioavailable small molecules

Sep. 19, 2018

Bavarian Nordic initiates phase II study of CV-301 with atezolizumab for bladder cancer

Sep. 19, 2018

NIDA award supports Ensysce's development of opioid overdose protection platform

Sep. 19, 2018

Investigators unveil BRWD1 gene mutation behind primary ciliary dyskinesia

Sep. 19, 2018

ARCA Biopharma submits SPA to FDA for phase III trial of Gencaro in atrial fibrillation

Sep. 19, 2018

Phase I results with ContraVir's CRV-431 support further development for HBV

Sep. 19, 2018

Encouraging results seen in CHAMPIONS study of SB-913 in mucopolysaccharidosis type II

Sep. 19, 2018

Enrollment begins in phase Ib/IIa study of BioAegis' rhu-pGSN

Sep. 19, 2018

FDA approves Utility's INDs for mecillinam and pivmecillinam

Sep. 19, 2018

CAM-2038 delivers durable pain relief in opioid-experienced patients in phase III trial

Sep. 19, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...